INTRODUCTION {#sec1-1}
============

Menopause is a universal and irreversible part of the overall aging process involving a woman\'s reproductive system and affects her physical and mental health in the form of various vasomotor and psychosexual symptoms. Hormone replacement therapy with agents such as estradiol is effective in reducing these symptoms, but interest in nonhormonal therapies has increased recently. Till date hormone replacement therapy is the only Food and Drug Administration (FDA) approved treatment for postmenopausal symptoms, but recent primary and secondary prevention trials show associated increased risk of coronary disease, thromboembolism, and stroke.\[[@ref1]\] Women Health Initiative (WHI) also points towards increased risk of breast cancer and slight increased risk of Alzheimer disease with HRT.\[[@ref2]\] Recent evidence-based reviews of complementary and alternative therapies and non-hormonal agents conclude that there are insufficient data regarding their effectiveness.\[[@ref3][@ref4]\] There is little emerging evidence in literature regarding gabapentin, an F-aminobutyric acid, for treatment of hot flushes, but therapy is still evolving.\[[@ref5][@ref6][@ref7][@ref8]\] Gabapentin is FDA approved for many neurological conditions like neuralgia and epilepsy. However, the role of gabapentin in menopausal psychosexual and somatic symptoms has not been studied much. Hence, this study was undertaken to assess the efficacy of gabapentin in these postmenopausal symptoms.

MATERIALS AND METHODS {#sec1-2}
=====================

This was a pilot study conducted in Department of Obstetrics and Gynecology at a tertiary care hospital from October 2009 to March 2011. Ethical clearance was obtained from institutional ethical committee. Fifty women with natural or surgical menopause presenting to menopause clinic of tertiary care center were recruited in the study after taking informed consent. Complete menstrual, obstetric, and medical history was taken. Presence and severity of menopausal symptoms were noted. Each patient underwent a thorough general and gynecological examination and a battery of investigations: Blood sugar, lipid profile, Pap smear, mammography as screening investigations; ultrasonography to evaluate endometrial thickness and any associated genital pathology.

Inclusion criteria were age between 45 and 55 years, no menses for ≥1 year, serum follicle stimulating hormone level of ≥40 mIU/ml, clinically normal pelvic examination, and normal Pap smear with any of the following psychosomatic and sexual symptoms like insomnia, fatigue, depression, irritability, nervousness, vaginitis, or dyspareunia. Exclusion criteria were asymptomatic women, abnormal screening investigations, prior hormonal or antidepressant treatment in last 6 months, and renal or liver disorders.

Randomization {#sec2-1}
-------------

Total 58 women were recruited out of which eight were excluded due to elevated thyroid-stimulating hormone (TSH; *n* = 4), not willing for follow-up (*n* = 2), currently on hormone therapy (*n* = 2). Rest 50 women were randomized into two groups using computerized randomization table. Opaque envelope method was used to assign the randomization group.

Intervention {#sec2-2}
------------

Detailed history was taken regarding presence of psychosexual (anxiety, depression, vaginal dryness, and dyspareunia) and somatic symptoms (insomnia, fatigue, lethargy, body aches, and heaviness) and their baseline severity. Psychological, sexual, and somatic symptoms were recorded and graded on Likert scale by putting self-administered questionnaire to the patient as 0-4 for absent, mild, moderate, and severe symptoms, respectively \[[Table 1](#T1){ref-type="table"}\]. Pretrial investigations included all baseline blood chemistry along with fasting lipid profile. Group I patients received gabapentin 900 mg/day (300 mg thrice daily) along with tablet calcium 500 mg once daily. Group II patients received only tablet calcium (500 mg once daily). Gabapentin was gradually increased from once daily at bedtime to thrice daily 1^st^ week to avoid the side effects. Similar tapering was also required during discontinuation of therapy. Patients were asked to keep record of symptoms.

###### 

Grading of various psychosexual and somatic symptoms
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Follow up {#sec2-3}
---------

Follow-ups were made after 1, 3, and 6 months of therapy. At each follow-up, symptoms were questioned and scored and any adverse effects were assessed. At 6 months follow-up, serum chemistry and fasting lipid profile were repeated.

Outcome measures {#sec2-4}
----------------

At the end of study, data was analyzed in terms of percentage reduction of psychosomatic and sexual symptoms. Change in lipid profile or any alteration in hemoglobin, total protein, and urea/creatinine was measured between baseline and at the end of study. The study protocol is depicted in [Figure 1](#F1){ref-type="fig"}.

![Consort flowchart](JMH-6-10-g002){#F1}

Statistical analysis {#sec2-5}
--------------------

Data was analyzed using Statistical Package for Social Sciences (SPSS)15. Changes in continuous parameters were analyzed by repeated measure analysis of variance (ANOVA)/Friedman test within groups and by independent *t*-test/Wilcoxon rank-sum test between the two groups. Multiple comparisons were done by Wilcoxon signed-rank test with Bonferroni correction. Categorical variables between two groups were compared by chi-square test/Fischer\'s exact test. *P*-value \<0.05 was taken as statistically significant.

RESULT {#sec1-3}
======

All baseline characteristics were comparable in participants of both groups. No statistical difference was found between groups in terms of age or participant distribution in natural and surgical menopause (*P* = 0.37). Duration of menopause was comparable in both groups (*P* = 0.11). Baseline lipid profile and TSH values were comparable too \[[Table 2](#T2){ref-type="table"}\].

###### 

Baseline characteristics of cases in both groups
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Maximum improvement was observed in insomnia (90-98% improvement in Group I compared to marginal improvement of around 4% in Group II). Improvement in anxiety was noted by 40% at 1 month to a maximum of 49% at 3 months with marginal improvement noted beyond, in Group I. While in Group II, maximum improvement noted was around 20% (18.6, 19.7, and 20% at 1, 3, and 6 months, respectively). Similarly for depression, improvement was seen by 40.4% at 1 month, 47% at 3 months, and 49.5% at 6 months in Group I; while it was \<20% (15.4, 16.6, and 17% at 1, 3, and 6 months, respectively) in Group II. No significant improvement in vaginal dryness and dyspareunia noted at all follow-ups in either group. Somatic symptoms reduced by 33, 36.8, and 40% at 1, 3, and 6 months, respectively, in Group I compared to18% improvement at all follow-up in Group II \[[Table 3](#T3){ref-type="table"}\].

###### 

Comparison of improvement in psychosomatic and sexual symptoms in Group I (gabapentin) and II (placebo) at 1, 3, and 6 month follow-up
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No significant change in serum cholesterol was found between baseline and at end of therapy in both groups, neither was there any significant difference in serum triglycerides in both the groups. Serum low density lipoprotein (LDL) increased significantly in Group I from baseline mean of 107.2 ± 21.4 to 113.7 ± 22.5 mg/dl at 6 months (*P* = 0.003). High density lipoprotein (HDL) increased significantly in Group II from 48.9 ± 4.3 at baseline to 53.2 ± 2.4 mg/dl at 6 months (*P* = 0.001). No statistical difference in hemoglobin, urea, creatinine, or total protein was noted within the groups between baseline and at 6 months (*P* ≥ 0.05) \[[Table 4](#T4){ref-type="table"}\].

###### 

Various serum values in both the groups before any intervention and at the end of the study
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Adverse effects {#sec2-6}
---------------

None of the patients had major adverse effects. Thirty-two percent women had side effects with gabapentin. None of the patients withdrew from the study due to side effects. Sixteen percent patients in Group I had noted headache (one episode/week) after starting gabapentin therapy in 1^st^ month, which responded to simple analgesics and no further episodes of headache were noted; 8% women complained of dizziness, however not so severe to discontinue the therapy; and 8% complained of somnolence during daily activities in 1^st^ week, gradually settled over a week without any further complaints, however night time sleep duration were found to be prolonged by 1-2 h, no such complaints were noted in women of Group II.

DISCUSSION {#sec1-4}
==========

Gabapentin has been found to be effective in reducing hot flush frequency and severity in postmenopausal women and was first reported by Guttuso in 2000, as an anecdotal experience.\[[@ref7]\] Role of gabapentin for management of psychosomatic and sexual symptoms is in a naive stage. We evaluated the effect of gabapentin in management of psychosomatic and sexual symptoms and found that maximum improvement was noted in insomnia. It was observed that psychosomatic symptoms improved with gabapentin therapy, but no improvement was observed in sexual symptoms.

In our study, two to 2.5-folds improvement in anxiety and depression was noted in women in gabapentin group as compared to placebo group. Guttuso *et al*., in 2003 had evaluated the effect of gabapentin 900 mg and reported that it does not affect the tension or anxiety subscale or total mood disturbance score, compared to placebo (*P* ≥ 0.05). Although the tension score and profile of mood state tension/anxiety subscale (POMS scale) were lesser in gabapentin group as compared to placebo group, statistical significance was not achieved.\[[@ref7]\] Reddy *et al*., also measured the effect of gabapentin, estrogen, and placebo on depression by Zung depression scale and measured no significant difference between the groups.\[[@ref8]\]

We also studied improvement insomatic symptoms in postmenopausal symptoms with gabapentin therapy. Patients in gabapentin group had 33, 36.8, and 40% improvement at 1, 3, and 6 months, respectively, comparedto18% improvement at all follow-up in placebo group accounting to a significant improvement. Guttuso *et al*., compared the effect of gabapentin vs placebo for somatic complaints on Greene Climacteric Scale and reported an increase in somatic complaints.\[[@ref7]\] Agarwal *et al*., recorded the reduction in somatic symptoms by 14.9, 56.6, and 80.8% at 1, 3, and 6 months, respectively, with transdermal estrogen patch.\[[@ref9]\]

When evaluation of improvement in sexual symptoms with gabapentin therapy was done in our study, improvement in vaginal dryness and dyspareunia ranged from 0 to 20% at all follow-up in both the groups, but no overall improvement was noted. Another study that recorded the improvement in sexual symptoms was by Butt *et al*., in which gabapentin 900 mg was compared with placebo.\[[@ref10]\] They reported a decreasing trend in the sexual score in the gabapentin group as compared to placebo group. Agarwal *et al*., recorded the reduction in sexual symptoms by use of transdermal estrogen patch.\[[@ref9]\] Hence, hormone therapy has greater efficacy compared to gabapentin in all the symptoms but on benefit-risk ratio ground nonhormonal agents had been evaluated.

Our study is the only one in which the effect of gabapentin on lipid profile is evaluated. No significant change in serum cholesterol and triglycerides was noted at end of therapy in both groups. Statistically significant increase was noted in serum LDL level in gabapentin group; however, no significant difference was noted in placebo group. Increase in HDL was also noted in gabapentin group; whereas, no significant difference was noted in placebo group. No significant difference was noted in hemoglobin, urea, and creatinine or total protein. Only one study that had compared these parameters was by Guttuso *et al*.\[[@ref7]\] They found significant decrease in total protein between baseline and 6 months in gabapentin group. They also found urea levels to be decreased in gabapentin group as compared to placebo at the end of 6 months of therapy. However, no significant difference in creatinine was found between both groups.

In our study, 32% women noted side effects in gabapentin group in the form of headache, dizziness, and somnolence. Guttuso *et al*., also reported somnolence and dizziness during initial weeks of therapy with gabapentin. Also, they reported decrease in total serum protein in gabapentin group unlike in our study, in which no such effect was seen. Peripheraledema was reported in 3% patients in their study.\[[@ref7]\] Overall, 13% women withdrew from their study mainly due to dizziness, while in our study no women withdrew due to side effects. Pandya *et al*., compared the treatment side effects with various doses of gabapentin and reported higher incidence of somnolence with 900 mg, 300 mg, and placebo in that order.\[[@ref5]\] Butt *et al*., reported greater incidence of dizziness, unsteadiness, and drowsiness at 1^st^ week of therapy with gabapentin as compared with placebo. However, these symptoms improved by 2^nd^ week and were comparable at 4^th^ week with baseline levels.\[[@ref10]\] Our study reported a rise in LDL level with gabapentin therapy; hence, it needs to be monitored during therapy, especially in patients with deranged lipid profile.

Considering the beneficial effects of gabapentin on psychosomatic symptoms with minimal side effects as compared to hormonal agents, this can be used in selected women. Usefulness in improvement of sexual symptoms in postmenopausal women was not reported in our study.

CONCLUSION {#sec1-5}
==========

Gabapentin can lead to improvement in menopausal psychosomatic symptoms. Sexual symptoms show no relief. As gabapentin can lead to increase in LDL cholesterol, precaution should be taken in patients with deranged lipid profile before starting therapy and it should be checked during course of therapy. This drug can cause minor side effects, though major side effects were reported in our study. Hence, gabapentin can be a better treatment option among the nonhormonal agents as an alternative to hormone therapy for management of some postmenopausal symptoms. Further studies and well-planned trials are required to validate this observation.
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